Description: LegoChem Biosciences, Inc. a biopharmaceutical company, focuses on the development of novel therapeutics utilizing its proprietary LegoChemistry medicinal drug discovery technology and antibody-drug conjugate platform (ADC). It engages in the research and development of ADC, anti-biotic, anti-coagulant, and anti-cancer therapeutics. The company offers its products in the forms of tablets and capsules. It has a research collaboration and license agreement with Iksuda Therapeutics for the development of antibody-drug conjugates in oncology. The company was founded in 2006 and is headquartered in Daejeon, South Korea.
Home Page: www.legochembio.com
8-26 Munpyeongseo-ro
Daejeon,
34302
South Korea
Phone:
82 4 2861 0688
Officers
| Name | Title |
|---|---|
| Mr. Yong-Zu Kim | Chief Exec. Officer and Pres |
| Mr. Sejin Park | Chief Financial Officer and VP |
| Mr. Yeong Soo Oh | Chief Technology Officer and Exec. VP |
| Young Lag Cho | Head Researcher |
| Ho Yong Song | Head Researcher |
| Hyang Sook Lee | Head Researcher |
| Dae Yeon Lee | Head Researcher |
Exchange: KQ
Country: KR : Korea (Republic of)
Currency: Korean Won (₩)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Life Sciences Tools & Services |
| GIC Sub-Industry: | Life Sciences Tools & Services |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0 |
| Price-to-Sales TTM: | 9.512 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 0 |